- Trials with a EudraCT protocol (57)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
57 result(s) found for: Hereditary angioedema.
Displaying page 1 of 3.
EudraCT Number: 2005-000206-31 | Sponsor Protocol Number: C1 1304-01 | Start Date*: 2004-06-22 | |||||||||||
Sponsor Name:PHARMING TECHNOLOGIES B.V. | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema | |||||||||||||
Medical condition: hereditary angioedema (HAE) treatment | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024242-30 | Sponsor Protocol Number: CE1145_4001 | Start Date*: 2011-10-06 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: Prospective open-label uncontrolled multi-center post-marketing study to assess inhibitory antibody formation in subjects with congenital C1-INH deficiency and acute hereditary angioedema (HAE) att... | |||||||||||||
Medical condition: congenital C1-INH deficiency and acute hereditary angioedema (HAE) attacks | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001054-42 | Sponsor Protocol Number: CSL830_3002 | Start Date*: 2015-03-04 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of ... | |||||||||||||
Medical condition: Hereditary Angioedema Types I and II | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001186-17 | Sponsor Protocol Number: CE1145_3001 | Start Date*: 2005-09-05 | |||||||||||
Sponsor Name:ZLB Behring GmbH | |||||||||||||
Full Title: Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks | |||||||||||||
Medical condition: Hereditary angioedema (HAE) is characterized by congenital C1-INH deficiency. This is reflected by insufficient plasma concentrations of C1 – inhibitor or by synthesis of dysfunctional C1 – inhibit... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) ES (Completed) CZ (Completed) SE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000916-10 | Sponsor Protocol Number: CSL830_3001 | Start Date*: 2013-12-10 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the pro... | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) type I and II | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) IT (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003603-18 | Sponsor Protocol Number: 331-201 | Start Date*: 2022-10-06 | ||||||||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | ||||||||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING1, in Su... | ||||||||||||||||||
Medical condition: Hereditary Angioedema (HAE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001693-28 | Sponsor Protocol Number: CONE-01 | Start Date*: 2020-02-06 | |||||||||||||||||||||
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H. | |||||||||||||||||||||||
Full Title: Prospective, open-label, single arm, multicenter, pharmacokinetic, and safety study of a single dose intravenous human plasma-derived C1 Esterase Inhibitor (C1-INH) concentrate in patients with con... | |||||||||||||||||||||||
Medical condition: Hereditary angioedema type I and type II | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002453-29 | Sponsor Protocol Number: 0624-301 | Start Date*: 2014-03-05 | |||||||||||
Sponsor Name:Shire ViroPharma Incorporated | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, SINGLE-BLIND, DOSE-RANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE... | |||||||||||||
Medical condition: Prevention of angioedema attacks in children 6 to 11 years of age with hereditary angioedema. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000987-92 | Sponsor Protocol Number: C11209 | Start Date*: 2011-09-26 | |||||||||||
Sponsor Name:Pharming Technologies B.V. | |||||||||||||
Full Title: Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patien... | |||||||||||||
Medical condition: Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) SK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003281-27 | Sponsor Protocol Number: BCX7353-204 | Start Date*: 2017-12-27 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||
Full Title: An Open-Label study to Evaluate the Long-Term Safety of Daily Oral BCX7353 in subjects with Type I and II Hereditary Angioedema | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) DK (Completed) AT (Completed) ES (Completed) SK (Completed) PL (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000605-24 | Sponsor Protocol Number: CSL312_2001 | Start Date*: 2018-12-20 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled, parallel-arm study to investigate the efficacy, pharmacokinetics, and safety of CSL312 in subjects with hereditary angioedema | |||||||||||||
Medical condition: Hereditary angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003918-12 | Sponsor Protocol Number: CSL312_3002 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | |||||||||||||
Medical condition: Hereditary angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004230-37 | Sponsor Protocol Number: BCX7353-312 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||
Full Title: An open-label study to provide berotralstat access to subjects with type 1 and 2 hereditary angioedema who were previously enrolled in berotralstat studies | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000197-14 | Sponsor Protocol Number: ISIS721744-CS3 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000570-25 | Sponsor Protocol Number: CSL312_3001 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic tr... | |||||||||||||
Medical condition: Hereditary angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) NL (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019670-32 | Sponsor Protocol Number: B1 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency and Frequent Hereditary Angioedema (HAE) Attacks. | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003819-71 | Sponsor Protocol Number: DX-88/14 | Start Date*: 2006-11-23 |
Sponsor Name:Dyax Corp | ||
Full Title: EDEMA3: Evaluation of DX-88’s Effects in Mitigating Angioedema A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 (recombinant pl... | ||
Medical condition: Hereditary Angioedema | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022716-39 | Sponsor Protocol Number: DX-88/26 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dyax Corp. | |||||||||||||
Full Title: A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002478-19 | Sponsor Protocol Number: SHP616-300 | Start Date*: 2016-06-28 | |||||||||||
Sponsor Name:Shire ViroPharma, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Este... | |||||||||||||
Medical condition: hereditary angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003139-38 | Sponsor Protocol Number: CE1145_3003 | Start Date*: 2015-02-12 | |||||||||||
Sponsor Name:ZLB Behring GmbH | |||||||||||||
Full Title: Open-label extension study of CE1145 (Human pasteurized C1 esterase inhibitor concentrate) in subjects with congenital C1-INH deficiency and acute HAE attacks | |||||||||||||
Medical condition: Congenital C1-INH deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
